Sakthivel Vaiyapuri

Prof. Sakthivel Vaiyapuri

University of Reading, UK
orcid

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
Sakthivel VaiyapuriSakthivel Vaiyapuri
Sakthivel Vaiyapuri
RVRajendran Vaiyapuri
Rajendran Vaiyapuri
RARajesh Ashokan
Rajesh Ashokan
KRKarthikeyan Ramasamy
Karthikeyan Ramasamy
KNKameshwaran Nattamaisundar
Kameshwaran Nattamaisundar
EHE. Gail Hutchinson
E. Gail Hutchinson
Snakebite represents a significant health issue worldwide, affecting several million people each year with as many as 95,000 deaths. India is considered to be the country most affected, but much remains unknown about snakebite incidence in this country, its socio-economic impact and how snakebite management could be improved. We conducted a study within rural villages in Tamil Nadu, India, which combines a household survey (28,494 people) of snakebite incidence with a more detailed survey of victims in order to understand the health and socio-economic effects of the bite, the treatments obtained and their views about future improvements. Our survey suggests that snakebite incidence is higher than previously reported. 3.9% of those surveyed had suffered from snakebite and the number of deaths corresponds to 0.45% of the population. The socio-economic impact of this is very considerable in terms of the treatment costs and the long-term effects on the health and ability of survivors to work. To reduce this, the victims recommended improvements to the accessibility and affordability of antivenom treatment. Snakebite has a considerable and disproportionate impact on rural populations, particularly in South Asia. This study provides an incentive for researchers and the public to work together to reduce the incidence and improve the outcomes for snake bite victims and their families.

20 June 2019 in Toxins
Verified
Journal Article
Open access
PDF file
HWHarry Fonseca Williams
Harry Fonseca Williams
HLHarry J. Layfield
Harry J. Layfield
TVThomas Vallance
Thomas Vallance
KPKetan Patel
Ketan Patel
ABAndrew B. Bicknell
Andrew B. Bicknell
Sakthivel VaiyapuriSakthivel Vaiyapuri
Sakthivel Vaiyapuri
Snakebite envenoming (SBE) is a priority neglected tropical disease, which kills in excess of 100,000 people per year. Additionally, many millions of survivors also suffer through disabilities and long-term health consequences. The only treatment for SBE, antivenom, has a number of major associated problems, not least, adverse reactions and limited availability. This emphasises the necessity for urgent improvements to the management of this disease. Administration of antivenom is too frequently based on symptomatology, which results in wasting crucial time. The majority of SBE-affected regions rely on broad-spectrum polyvalent antivenoms that have a low content of case-specific efficacious immunoglobulins. Research into small molecular therapeutics such as varespladib/methyl-varespladib (PLA2 inhibitors) and batimastat/marimastat (metalloprotease inhibitors) suggest that such adjunctive treatments could be hugely beneficial to victims. Progress into toxin-specific monoclonal antibodies as well as alternative binding scaffolds such as aptamers hold much promise for future treatment strategies. SBE is not implicit during snakebite, due to venom metering. Thus, the delay between bite and symptom presentation is critical and when symptoms appear it may often already be too late to effectively treat SBE. The development of reliable diagnostical tools could therefore initiate a paradigm shift in the treatment of SBE. While the complete eradication of SBE is an impossibility, mitigation is in the pipeline, with new treatments and diagnostics rapidly emerging. Here we critically review the urgent necessity for the development of diagnostic tools and improved therapeutics to mitigate the deaths and disabilities caused by SBE.

17 October 2017 in Mediators of Inflammation
Verified
Journal Article
Open access
PDF file
TVThomas Vallance
Thomas Vallance
MZMarie-Theres Zeuner
Marie-Theres Zeuner
HWHarry Fonseca Williams
Harry Fonseca Williams
Darius WideraDarius Widera
Darius Widera
Sakthivel VaiyapuriSakthivel Vaiyapuri
Sakthivel Vaiyapuri
Platelets are anucleated blood cells that participate in a wide range of physiological and pathological functions. Their major role is mediating haemostasis and thrombosis. In addition to these classic functions, platelets have emerged as important players in the innate immune system. In particular, they interact with leukocytes, secrete pro- and anti-inflammatory factors, and express a wide range of inflammatory receptors including Toll-like receptors (TLRs), for example, Toll-like receptor 4 (TLR4). TLR4, which is the most extensively studied TLR in nucleated cells, recognises lipopolysaccharides (LPS) that are compounds of the outer surface of Gram-negative bacteria. Unlike other TLRs, TLR4 is able to signal through both the MyD88-dependent and MyD88-independent signalling pathways. Notably, despite both pathways culminating in the activation of transcription factors, TLR4 has a prominent functional impact on platelet activity, haemostasis, and thrombosis. In this review, we summarise the current knowledge on TLR4 signalling in platelets, critically discuss its impact on platelet function, and highlight the open questions in this area.

1 November 2015 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
ABAlexander P. Bye
Alexander P. Bye
AUAmanda Jan Unsworth
Amanda Jan Unsworth
Sakthivel VaiyapuriSakthivel Vaiyapuri
Sakthivel Vaiyapuri
ASAlexander R. Stainer
Alexander R. Stainer
MFMichael J. Fry
Michael J. Fry
JGJonathan M. Gibbins
Jonathan M. Gibbins
Objective—: Ibrutinib is an irreversible Bruton tyrosine kinase inhibitor approved for treatment of Waldenstrom macroglobulinemia, chronic lymphocytic leukemia, and mantle cell lymphoma that increases the risk of bleeding among patients. Platelets from ibrutinib-treated patients exhibit deficiencies in collagen-evoked signaling in suspension; however, the significance of this observation and how it relates to bleeding risk is unclear, as platelets encounter immobile collagen in vivo. We sought to clarify the effects of ibrutinib on platelet function to better understand the mechanism underlying bleeding risk. Approach and Results—: By comparing signaling in suspension and during adhesion to immobilized ligands, we found that the collagen signaling deficiency caused by ibrutinib is milder during adhesion to immobilized collagen. We also found that platelets in whole blood treated with ibrutinib adhered to collagen under arterial shear but formed unstable thrombi, suggesting that the collagen signaling deficiency caused by ibrutinib may not be the predominant cause of bleeding in vivo. However, clot retraction and signaling evoked by platelet adhesion to immobilized fibrinogen were also inhibited by ibrutinib, indicating that integrin α IIb β 3 outside-in signaling is also effected in addition to GPVI signaling. When ibrutinib was combined with the P2Y 12 inhibitor, cangrelor, thrombus formation under arterial shear was inhibited additively. Conclusions—: These findings suggest that (1) ibrutinib causes GPVI and integrin α IIb β 3 platelet signaling deficiencies that result in formation of unstable thrombi and may contribute toward bleeding observed in vivo and (2) combining ibrutinib with P2Y 12 antagonists, which also inhibit thrombus stability, may have a detrimental effect on hemostasis.

22 May 2012 in Circulation
Verified
Journal Article
Closed access
PDF file
Sakthivel VaiyapuriSakthivel Vaiyapuri
Sakthivel Vaiyapuri
CJChris Jones
Chris Jones
PSParvathy Sasikumar
Parvathy Sasikumar
LMLeonardo A. Moraes
Leonardo A. Moraes
SMStephanie J. Munger
Stephanie J. Munger
JGJonathan M. Gibbins
Jonathan M. Gibbins
Background—: Connexins are a widespread family of membrane proteins that assemble into hexameric hemichannels, also known as connexons. Connexons regulate membrane permeability in individual cells or couple between adjacent cells to form gap junctions and thereby provide a pathway for regulated intercellular communication. We have examined the role of connexins in platelets, blood cells that circulate in isolation but on tissue injury adhere to each other and the vessel wall to prevent blood loss and to facilitate wound repair. Methods and Results—: We report the presence of connexins in platelets, notably connexin37, and that the formation of gap junctions within platelet thrombi is required for the control of clot retraction. Inhibition of connexin function modulated a range of platelet functional responses before platelet-platelet contact and reduced laser-induced thrombosis in vivo in mice. Deletion of the Cx37 gene ( Gja4 ) in transgenic mice reduced platelet aggregation, fibrinogen binding, granule secretion, and clot retraction, indicating an important role for connexin37 hemichannels and gap junctions in platelet thrombus function. Conclusions—: Together, these data demonstrate that platelet gap junctions and hemichannels underpin the control of hemostasis and thrombosis and represent potential therapeutic targets.

9 November 2018 in Blood Advances
Verified
Journal Article
Open access
PDF file
MSMaryam F. Salamah
Maryam F. Salamah
DRDivyashree Ravishankar
Divyashree Ravishankar
XKXenia Kodji
Xenia Kodji
LMLeonardo A. Moraes
Leonardo A. Moraes
HWHarry F. Williams
Harry F. Williams
Sakthivel VaiyapuriSakthivel Vaiyapuri
Sakthivel Vaiyapuri
Platelet-associated complications including thrombosis, thrombocytopenia, and hemorrhage are commonly observed during various inflammatory diseases such as sepsis, inflammatory bowel disease, and psoriasis. Despite the reported evidence on numerous mechanisms/molecules that may contribute to the dysfunction of platelets, the primary mechanisms that underpin platelet-associated complications during inflammatory diseases are not fully established. Here, we report the discovery of formyl peptide receptor 2, FPR2/ALX, in platelets and its primary role in the development of platelet-associated complications via ligation with its ligand, LL37. LL37 acts as a powerful endogenous antimicrobial peptide, but it also regulates innate immune responses. We demonstrate the impact of LL37 in the modulation of platelet reactivity, hemostasis, and thrombosis. LL37 activates a range of platelet functions, enhances thrombus formation, and shortens the tail bleeding time in mice. By utilizing a pharmacological inhibitor and Fpr2/3 (an ortholog of human FPR2/ALX)–deficient mice, the functional dependence of LL37 on FPR2/ALX was determined. Because the level of LL37 is increased in numerous inflammatory diseases, these results point toward a critical role for LL37 and FPR2/ALX in the development of platelet-related complications in such diseases. Hence, a better understanding of the clinical relevance of LL37 and FPR2/ALX in diverse pathophysiological settings will pave the way for the development of improved therapeutic strategies for a range of thromboinflammatory diseases.